A Methacrylic Hyaluronic Acid Derivative for Potential Application in Oral Treatment of Celiac Disease.

A Methacrylic Hyaluronic Acid Derivative for Potential Application in Oral Treatment of Celiac Disease.

Drug Dev Ind Pharm. 2017 Apr 13;:1-29

Authors: Pitarresi G, Palumbo FS, Triolo D, Fiorica C, Giammona G

Abstract
OBJECTIVE: Aim of this work was the synthesis of a methacrylic hyaluronic acid derivative and the production, via photocrosslinking, of related hydrogels loaded with an endopeptidase intended for a potential oral treatment of celiac disease.
METHODS: The methacrylic derivative of hyaluronic acid (HA) was prepared through a one-pot procedure involving the reaction with ethylenediamine (EDA) and methacrylic anhydride (MA). The obtained derivative, named HA-EDA-MA, was used to prepare photocrosslinked hydrogels loaded with a prolyl endopeptidase derived from Flavobacterium meningosepticum (PEP FM) able to detoxify gliadin. Obtained hydrogels were recovered as gels or freeze dried powders.
RESULTS: Hydrogels obtained as freeze dried powders, are able to protect loaded enzyme from degradation due to freeze drying process and from alteration during storage, overall in the presence of a cryoprotectant. All photocrosslinked HA-EDA-MA hydrogels (gels and powders) release PEP FM in simulated intestinal fluid in sustained manner and in active form. HA-EDA-MA hydrogels are non-toxic as demonstrated through in vitro studies on BALB 3T3 cells.
CONCLUSIONS: Prepared hydrogels show a potential application for oral treatment of celiac disease thanks to the possibility to release enzymes able to detoxify the gliadin peptide that induces the immunogenic response.

PMID: 28406045 [PubMed - as supplied by publisher]

http://ift.tt/2nM28A9